January 2011 
Volume 41  Number 1
Pages 15 - 15
  PDF Version Available!

Because the risk of cardiac toxicity outweighs the pain relief benefit, the FDA has asked manufacturers of Darvon, Darvocet, and generic versions of the prescription opioid propoxyphene to voluntarily remove the drug from the market. A new study has shown that even when taken at recommended doses, propoxyphene may cause prolonged PR intervals, widened QRS complexes, and prolonged QT intervals, increasing the risk of serious dysrhythmias and sudden death. Data also indicate that the risk of adverse reactions for patients who've taken the drug for years can change based on small changes to the patient's health status, such as dehydration, a change in medications, or decreased renal function.The FDA urges healthcare professionals to stop prescribing and dispensing products containing propoxyphene. Tell patients currently taking the drug to contact their healthcare providers to discuss risks and find an alternative treatment.Source: U.S. Food and Drug Administration. Xanodyne agrees to withdraw

Purchase Now !

To purchase this item, follow the instructions below. If you’re not already logged in, be sure to enter your login information below to ensure that your item is saved to your File Drawer after you purchase it.

Not a member? Join now for Free!

1) If you're not already logged in, enter your information below to save this item in your File Drawer for future viewing.

User name:


Forgot your user name or password?
2)  If you have a coupon or promotional code, enter it
here.(If not, just click Continue.

Digital Coupon: (optional)

3)  Click Continue to go to the next screen, where
you'll enter your payment details.

jQuery UI Accordion - Default functionality

For life-long learning and continuing professional development, come to Lippincott's NursingCenter.

Nursing Jobs Plus
Featured Jobs
Recommended CE Articles Recommended Nursing Articles Evidence Based Practice Skin Care Network NursingCenter Quick Links What’s Trending Events